beta-Lactamase Inhibitors
"beta-Lactamase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Endogenous substances and drugs that inhibit or block the activity of BETA-LACTAMASES.
| Descriptor ID |
D065093
|
| MeSH Number(s) |
D27.505.519.389.400 D27.505.954.122.085.516
|
| Concept/Terms |
beta-Lactamase Inhibitors- beta-Lactamase Inhibitors
- Inhibitors, beta-Lactamase
- beta Lactamase Inhibitors
- Inhibitors, beta Lactamase
- Lactamase Inhibitors, beta
- beta Lactamase Antagonists
- Antagonists, beta Lactamase
- Lactamase Antagonists, beta
|
Below are MeSH descriptors whose meaning is more general than "beta-Lactamase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "beta-Lactamase Inhibitors".
This graph shows the total number of publications written about "beta-Lactamase Inhibitors" by people in this website by year, and whether "beta-Lactamase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 2 | 0 | 2 |
| 1999 | 1 | 0 | 1 |
| 2000 | 1 | 1 | 2 |
| 2001 | 1 | 1 | 2 |
| 2003 | 1 | 1 | 2 |
| 2004 | 1 | 0 | 1 |
| 2009 | 1 | 0 | 1 |
| 2010 | 1 | 0 | 1 |
| 2011 | 3 | 0 | 3 |
| 2012 | 3 | 0 | 3 |
| 2013 | 2 | 0 | 2 |
| 2014 | 1 | 0 | 1 |
| 2015 | 0 | 1 | 1 |
| 2016 | 1 | 0 | 1 |
| 2018 | 0 | 1 | 1 |
| 2019 | 3 | 0 | 3 |
| 2020 | 3 | 3 | 6 |
| 2021 | 2 | 0 | 2 |
| 2022 | 1 | 1 | 2 |
| 2023 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "beta-Lactamase Inhibitors" by people in Profiles.
-
Exploiting the Carboxylate-Binding Pocket of ?-Lactamase Enzymes Using a Focused DNA-Encoded Chemical Library. J Med Chem. 2024 01 11; 67(1):620-642.
-
Genetic determinants underlying the progressive phenotype of ?-lactam/?-lactamase inhibitor resistance in Escherichia coli. Microbiol Spectr. 2023 Dec 12; 11(6):e0222123.
-
A novel method to evaluate ceftazidime/avibactam therapy in patients with carbapenemase-producing Enterobactericeae (CPE)?bloodstream infections. Int J Antimicrob Agents. 2023 Apr; 61(4):106760.
-
Optimal ceftazidime/avibactam dosing exposure against KPC-producing Klebsiella pneumoniae. J Antimicrob Chemother. 2022 10 28; 77(11):3130-3137.
-
Evaluation of the inoculum effect of new antibiotics against carbapenem-resistant enterobacterales. Clin Microbiol Infect. 2022 Nov; 28(11):1503.e1-1503.e3.
-
Consensus on ?-Lactamase Nomenclature. Antimicrob Agents Chemother. 2022 04 19; 66(4):e0033322.
-
Inoculum effect of Enterobacterales co-expressing OXA-48 and CTX-M on the susceptibility to ceftazidime/avibactam and meropenem. Eur J Clin Microbiol Infect Dis. 2022 May; 41(5):853-858.
-
Deep Sequencing of a Systematic Peptide Library Reveals Conformationally-Constrained Protein Interface Peptides that Disrupt a Protein-Protein Interaction. Chembiochem. 2022 02 04; 23(3):e202100504.
-
Optimizing pharmacokinetics/pharmacodynamics of ?-lactam/?-lactamase inhibitor combinations against high inocula of ESBL-producing bacteria. J Antimicrob Chemother. 2021 01 01; 76(1):179-183.
-
New ?-Lactam-?-Lactamase Inhibitor Combinations. Clin Microbiol Rev. 2020 12 16; 34(1).